Group 1 - Strategic partnership established between Dongyangguang Pharmaceutical (06887) and Shenzhen Jingtai Technology on January 26, 2026 [1] - Joint venture to create an AI-driven drug research and development platform, focusing on innovative drug development for autoimmune diseases [1] - Development of PB-PK predictive large model and promotion of Dongyangguang's proprietary "HEC-SynAI drug synthesis model" and "HEC-PharmAI formulation model" [1] Group 2 - Innovation in business model through the establishment of an AI supercomputing platform, creating a "Model as a Service" (MaaS) business model [1] - Dongyangguang Pharmaceutical has 150 approved drugs and over 100 drugs in research, including nearly 50 first-class innovative drugs, leading in patent numbers among domestic pharmaceutical companies from 2014 to 2023 [1] - As of the announcement date, a formal agreement has not yet been signed, indicating uncertainty in the partnership [1]

Major Events - Dongpeng Beverage (09980) will conduct its IPO from January 26 to January 29, with an expected listing date of February 3 [1] - Zijin Mining (02899) plans to acquire 100% of Allied Gold Corporation for approximately CAD 5.5 billion [2] - AsiaInfo Technologies (01675) collaborates with ABB Robotics to establish an "Embodied Intelligence Laboratory" [3] - Dongyang Sunshine Pharmaceutical (06887) signs a strategic cooperation agreement with Shenzhen Jingtai to form a joint venture for an AI-driven drug research platform [4] - Howie Group (00501) intends to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [5] - Singularity Guofeng (01280) enters a GPU distribution cooperation agreement with Muxi Co., aiming to penetrate the domestic AI computing power market [6] - Guorui Life (00108) signs a strategic cooperation memorandum with Mingzhi Medical to promote deep integration and industrial upgrading of "medical + technology + scenarios" [7] Financial Reports - Harbin Electric (01133) anticipates a net profit attributable to shareholders of approximately CNY 2.65 billion for 2025 [8] - Joyson Electronics (00699) expects an annual net profit of about CNY 1.35 billion, representing a year-on-year growth of approximately 40.56% [9] - Guotai Junan International (01788) projects an annual net profit between HKD 1.28 billion and HKD 1.38 billion, a significant increase of 265% to 293% year-on-year [10] - Tianyue Advanced (02631) forecasts annual revenue of CNY 1.45 billion to CNY 1.5 billion [11] - China Power (02380) estimates a consolidated total electricity sales volume of approximately 126 million megawatt-hours for 2025 [12] - Chalco International (02068) expects a total new contract amount of CNY 46.836 billion for 2025, a year-on-year increase of 51.94% [13]

Company News - China Power (02380.HK) expects a total consolidated electricity sales volume of 10.73105 million MWh by December 2025, a decrease of 2.31% year-on-year; the total annual electricity sales volume is approximately 126 million MWh, down 1.27% year-on-year [2] - Harbin Electric (01133.HK) anticipates a net profit attributable to shareholders of approximately RMB 2.65 billion for the fiscal year 2025, compared to RMB 1.686 billion in the previous year, mainly due to increased operating revenue and improved product profitability [2] - Singularity Guofeng (01280.HK) has entered into a GPU distribution cooperation agreement with Muxi Co., aiming to enter the domestic AI computing power market [2] - Dongyang Sunshine Pharmaceutical (06887.HK) has signed a strategic cooperation agreement with Shenzhen Jingtai to establish a joint venture for building an AI-driven drug research and development platform [2] - Weisheng Pharmaceutical-B (02561.HK) has received approval from the National Medical Products Administration for the marketing authorization application of injectable Long Pei growth hormone [2] - Kintor Pharmaceutical-B (02171.HK) issued a profit warning, expecting a net loss for 2025 to be reduced to no more than approximately RMB 120 million [2] - Zhaoke Ophthalmology-B (06622.HK) is advancing the commercialization process of BRIMOCHOL PF for treating presbyopia in Singapore and Vietnam through partnerships with AFT and Qianshou [2] Additional Company Developments - Heng Rui Medicine (01276.HK) has received a clinical trial approval notice for SHR-1049 injection [3] - Baolong Real Estate (01238.HK) has had its bond restructuring plan approved by the relevant bondholders' meeting [3] Strategic Partnerships - Yabo Technology Holdings (08279.HK) has entered into a technical service agreement with Hong Kong Gold Exchange Limited [4] - Future Data Group (08229.HK) has signed a strategic cooperation framework agreement with Linghe Culture [4] - Howey Group (00501.HK) plans to invest up to USD 50 million to subscribe for shares in Aixin Yuanzhi's initial public offering [4] Buyback Activities - Xiaomi Group-W (01810.HK) repurchased 3.9872 million shares for HKD 140 million, with a repurchase price ranging from HKD 35.04 to HKD 35.22 [5] - China Metallurgical Group (01618.HK) repurchased 9.011 million shares for HKD 16.9299 million, with a repurchase price of HKD 1.87 to HKD 1.88 [5] - Geely Automobile (00175.HK) repurchased 4.401 million shares for HKD 72.952 million, with a repurchase price ranging from HKD 16.43 to HKD 16.65 [6] - Reshape Energy (02570.HK) completed the placement of a total of 4.536 million placement shares, raising approximately HKD 258 million [6] - Kintor Pharmaceutical-B (09939.HK) saw an increase of 4.7 million shares by Chairman Tong Youzhi [6]

(1)成立联合实验室，联合开发创新药物管线 东阳光（600673）药(06887)发布公告，本公司于2026年1月26日与深圳晶泰科技有限公司(深圳晶泰)订 立战略合作协议(战略合作协议)。根据战略合作协议，双方拟成立合资公司，共建AI驱动药物研发平 台，聚焦以下合作： 依托深圳晶泰全球化的商业网络和AI平台产品化经验，推广本集团自主开发的"HEC-SynAI药物合成大 模型"和"HEC-PharmAI制剂大模型"，以及全新一代PB-PK大模型。 (3)创建"模型即服务"(MaaS)的商业模式 双方计划以"算力支撑+数据开发+生态共享"模式共建AI超算平台，向学界与业界开放合作成果，将数 据资产和AI产品转化为"模型即服务"(MaaS)的商业模式。 董事会认为，战略合作协议为订约方提供宝贵机会利用各自的资源及专业知识，为彼此创造互利及协同 效应。因此，董事会认为，签订战略合作协议符合本公司及其股东的整体利益。 双方共建联合实验室，以AI驱动的自动化为目标，依托深圳晶泰自动化实验平台技术和部署经验，实 现"设计—构建—测试—学习"研发闭环，聚焦自身免疫性疾病，共同发现候选药物并由合资公司推进。 (2)大模型联合 ...

Company Overview - InSilico Medicine, a biotechnology company, focuses on integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in the life sciences sector [1][3]. Recent Developments - On January 5, InSilico Medicine announced a multi-year research collaboration with Servier, a global independent pharmaceutical company, to utilize its AI platform Pharma.AI in the oncology field, aiming to identify and develop new therapeutic drugs [1]. - The agreement allows InSilico Medicine to receive up to $32 million in upfront and milestone payments while leading the discovery and development of potential drug candidates [1]. Strategic Partnerships - InSilico Medicine has established multiple collaborations with pharmaceutical companies, including Fosun Pharma, Sanofi, Eli Lilly, and Menarini, to integrate AI capabilities into drug development [3]. - The company plans to adopt a diversified business model, including drug development collaborations, pipeline licensing, and software licensing, which provides stable revenue and alleviates cash flow pressure from high R&D investments [3]. Industry Insights - The industry consensus acknowledges that AI algorithms can shorten the drug development cycle, although the specific integration paths remain unclear. The collaboration between InSilico Medicine and Servier may offer a viable approach [1][2]. - Several domestic biotech companies leveraging AI technology have begun to produce distinctive products, with potential for continued influence in overseas markets [4]. Future Outlook - InSilico Medicine's CEO emphasizes that AI is evolving from a tool to a foundational infrastructure for pharmaceutical companies, requiring long-term technical accumulation and solid clinical validation [5].

Core Insights - Insilico Medicine and TaiGen Biopharmaceuticals have entered into an exclusive licensing agreement for the PHD inhibitor ISM4808, aimed at treating anemia associated with chronic kidney disease (CKD) in Greater China [1][3]. Group 1: Partnership Details - TaiGen will receive exclusive rights for the development, commercialization, and sublicensing of ISM4808 in Greater China, while Insilico Medicine will receive upfront payments, milestone payments based on development and sales, and tiered royalties based on net sales, with the total transaction amount reaching tens of millions of dollars [3]. - The partnership is expected to leverage Insilico's AI-driven drug discovery capabilities, which have demonstrated efficiency in identifying new drug candidates [4]. Group 2: Product Information - ISM4808 is recognized as a candidate drug for PHD inhibition, targeting the HIF-α pathway, which has been awarded a Nobel Prize, and aims to induce EPO production and improve iron utilization to enhance red blood cell regeneration [3]. - The drug has shown strong efficacy in preclinical studies, with a lower effective dose validated in chronic kidney disease rat models, and has received clinical trial approval from China's CDE in 2023 [4]. Group 3: Market Potential - The market for PHD inhibitors is experiencing rapid growth, with the market size in mainland China increasing from 50 million RMB to 2.45 billion RMB over five years, indicating a significant demand for oral medications that replace traditional injectable therapies [4].

Group 1: IPO Developments - Moer Thread has officially launched its IPO on the Sci-Tech Innovation Board, with a stock code of "688795," and plans to start subscription on November 24, marking a significant step in China's high-end GPU chip sector [3][4] - Moer Thread is recognized as the only domestic company that has achieved mass production of full-function GPUs, with applications in various fields including AI model training, digital twin, and cloud computing [5] - Yushu Technology has completed its domestic IPO counseling and will soon submit its prospectus, focusing on high-performance quadrupedal and humanoid robots [7][8] Group 2: Company Highlights - Moer Thread's MUSA unified system architecture allows for simultaneous support of AI computing acceleration, graphics rendering, and other advanced functions, establishing a key technical benchmark in the domestic high-end AI chip sector [4] - Yushu Technology has reported annual revenues exceeding 1 billion yuan, maintaining profitability since 2020, with a significant portion of its sales coming from quadrupedal robots [9][8] - Insilico Medicine has updated its prospectus for its Hong Kong IPO, focusing on AI-driven drug development and has established partnerships with major pharmaceutical companies [14][15] Group 3: Market Performance - Seyond Holdings Ltd. (Tudatong) has passed its hearing and plans to list on the Hong Kong Stock Exchange on December 10, specializing in automotive-grade LiDAR solutions [11][12] - Tudatong has delivered approximately 181,131 automotive-grade LiDAR units in the first three quarters of the year, reflecting a year-on-year growth of 7.7% [11] - Insilico Medicine's revenue is projected to grow from $30.15 million in 2022 to $85.83 million in 2024, with a significant increase in gross margin from 63.4% to 90.4% over the same period [15]

Core Insights - Insilico Medicine has announced a strategic collaboration with multinational pharmaceutical company Eli Lilly to accelerate the discovery and development of innovative therapies using Insilico's AI drug discovery platform, Pharma.AI [1] Group 1: Collaboration Details - The partnership will leverage Insilico's advanced AI technology and Eli Lilly's extensive experience in drug development and disease research [1] - Insilico will generate, design, and optimize candidate compounds based on agreed innovative targets using the Pharma.AI platform [1] Group 2: Financial Aspects - Insilico is entitled to receive over $100 million (approximately 712 million RMB) from this collaboration, which includes upfront payments, milestone payments during research, and tiered royalties on net sales after commercialization of the drugs [1] Group 3: Historical Context - This collaboration marks an upgrade in the partnership between Insilico and Eli Lilly, following a software licensing agreement established earlier in 2023 based on the AI platform [1]

Core Viewpoint - The stock of Heptagon Pharmaceuticals (02142) rose over 5%, currently up 5.46% at HKD 13.94, with a trading volume of HKD 17.1969 million, following the announcement of a strategic partnership with Evinova at the 8th China International Import Expo [1] Group 1: Strategic Partnership - Heptagon Pharmaceuticals and Evinova announced a strategic cooperation to leverage AI and digital technologies to enhance the efficiency of innovative biotherapy development [1] - The partnership aims to build an AI-driven open ecosystem for drug research and development by utilizing each company's strengths [1] Group 2: AI Platform Development - Heptagon Pharmaceuticals launched its first fully human AIHCAb model driven by the Hu-mAtrIx™ AI platform during a global R&D day event in Shanghai [1] - The model is based on proprietary HarbourMice® platform data and integrates a fine-tuned large language model (LLM) for sequence generation, complemented by high-precision AI classification and drugability prediction models [1] - Unlike traditional screening methods, the platform achieves a closed-loop process of AI design, intelligent screening, and wet lab validation [1]

Core Insights - Insilico Medicine aims to become the first globally to have an AI-enabled drug candidate enter Phase III clinical trials [2][4] - The company has developed a dual-engine business model focusing on both AI platform licensing and internal pipeline development [6] Company Overview - Insilico Medicine, founded in 2014, is a global AI-driven biotech company that utilizes its Pharma.AI platform for drug discovery and development [2] - The company has expanded the application of its AI technology to various sectors, including advanced materials, agriculture, nutrition products, and veterinary medicine [2] Pipeline and Clinical Progress - The core asset, Rentosertib (ISM001-055), is a first-in-class candidate for idiopathic pulmonary fibrosis (IPF) and has shown positive results in Phase IIa clinical trials in China [3] - The drug has received breakthrough therapy designation from the Center for Drug Evaluation (CDE) in China, which may expedite its clinical development and review process [3][4] - Insilico Medicine has generated over 20 clinical or IND-stage assets through its Pharma.AI platform, with three assets licensed to international pharmaceutical companies, totaling over $2 billion in contract value [4] Financial Performance - Revenue projections for Insilico Medicine from 2022 to 2024 are $30.15 million, $51.18 million, and $85.83 million, respectively, with gross margins increasing from 63.4% to 90.4% [5] - The net loss is expected to decrease significantly from $222 million in 2022 to $17.1 million in 2024 [5] Funding and Use of Proceeds - As of June 30, 2025, the company's cash and equivalents increased from approximately $126 million at the end of 2024 to about $213 million, primarily due to a Series E financing round [7] - The net proceeds from the IPO will be used for further clinical development of key pipeline candidates, development of new generative AI models, and expansion of automated laboratories [7]